Melanoma is an aggressive skin cancer and a predominant cause of skin cancer-related deaths. This study investigates the anti-tumor effects of dipeptide-derivate compound (DDC) in a highly metastatic murine melanoma cell line. Cell viability was assessed using the MTT colorimetric assay. Metastatic capabilities including migration of B16F10 melanoma cells were examined by Transwell migration and intravasation. The Akt, ERK and IκB phosphorylation was used to investigate the possible mechanisms of DDC. Melanoma xenograft and lung metastasis mouse model were used to investigate the in vivo effect of DDC. We first demonstrated that DDC affects the cell viability. DDC does-dependently inhibited the migration and intravasation of B16F10 cells in vitro. DDC also dose-dependently affected the Akt, ERK and IκB phosphorylation in B16F10 cells. The in vivo effect of DDC was demonstrated in the melanoma model of B6 mice that was known as the most difficult tumor model to cure. DDC administration was significantly inhibited tumor growth and metastasis in B16F10 in vivo model. Taken together, these findings suggested that DDC could reduce the growth and metastasis of melanoma cells. in vitro and in vivo. DDC may be a promising therapeutic agent for melanoma.